CG 202

Drug Profile

CG 202

Alternative Names: CG202

Latest Information Update: 01 Feb 2017

Price : $50

At a glance

  • Originator ConverGene
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Bromodomain and extraterminal domain protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Haematological malignancies

Most Recent Events

  • 31 Jan 2017 CG 202 is available for licensing as of 31 Jan 2017. http://convergenepharma.com/product-development/
  • 31 Jan 2017 Preclinical trials in Haematological malignancies in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top